Why the study?
There is a lack of consensus on the optimal venous thromboembolism prophylaxis strategy in ischemic stroke due to few direct randomized controlled trials comparing interventions.
Do low-molecular-weight heparin and heparinoid reduce the risk of DVT and PE in patients with ischemic stroke?
Systematic Review
Do low-molecular-weight heparin and heparinoid reduce the risk of DVT and PE in patients with ischemic stroke?
In patients with acute ischemic stroke, LMWH and heparinoid significantly reduce the risk of DVT and PE but increase the risk of extracranial hemorrhage compared to no prophylaxis.
Supports LMWH/heparinoid prophylaxis in acute ischemic stroke; confirms DVT/PE reduction with extracranial bleeding caution.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT), and pulmonary embolism (PE), is a common complication in patients with ischemic stroke. Several prophylactic strategies are used to reduce the risk of VTE. However, there is still a lack of consensus on the optimal strategy due to the lack of randomized controlled trials (RCTs) directly comparing different interventions. The objective of this study was to explore the efficacy and safety of different thromboembolic prophylaxis strategies in patients with ischemic stroke. We conducted a systematic literature review to identify all eligible RCTs, searching MEDLINE and Embase up to December 31, 2024. We considered DVT and PE as efficacy outcomes and intracranial and extracranial hemorrhage as safety outcome measures. Relevant data were extracted for network meta-analyses. A random-effects model was used for the analysis. A total of 33 RCTs were included in the analysis. Network meta-analysis revealed that low-molecular-weight heparin (LMWH) and heparinoid were associated with significantly decreased risk of DVT and PE compared with no prophylaxis, with risk ratios of 0.18 (95% confidence interval: 0.10-0.32) and 0.36 (0.20-0.63), respectively. However, LMWH and heparinoid were associated with an increased risk of extracranial hemorrhage compared with no prophylaxis, with a risk ratio of 2.03 (1.24-3.34). Our study supports the use of LMWH and heparinoid as the primary thromboembolic prophylaxis measure in patients with acute ischemic stroke. Further, high-quality RCTs are needed to strengthen the evidence base and determine the optimal prophylactic strategy in these patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a systematic review in Ischemic Stroke. Venous Thromboembolic Prophylaxis Strategies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: